India Quotient

India Quotient is a Mumbai-based early-stage fund focused on disruptive consumer and B2B models, with documented exposure to AI-driven healthcare including CureSkin, the AI dermatology platform. Check sizes of $250k to $1M place the firm in the seed range, capable of leading small priced rounds. The firm has a real AI thematic lens.

The firm’s natural fit is with Indian founders building disruptive consumer or B2B platforms with credible AI moats and a clear path to scale. For healthcare founders specifically, the right profile is a team building AI-enabled consumer health platforms (dermatology, mental health, fitness, nutrition), AI-enabled clinical workflow software, or B2B health platforms with strong unit economics. Founders building deep biotech or pure US-market software without Indian commercial wedge are not the natural target.

Geographically, India Quotient’s advantage is its long Indian track record and its connectivity to follow-on Series A and B investors. The firm is among the more established Indian seed funds with multiple vintages and proven follow-on syndication capability. For Indian-anchored founders, the firm is a credible early partner. For non-Indian founders, the strategic logic is thin.

The right entry path is a warm intro from a portfolio founder, a fellow Indian VC, or a senior operator at one of the Indian unicorns. The firm reads partner-led decks and responds to clear AI-disruptive theses with credible early traction. The pitch should lead with the AI moat (data, model, customer outcomes), Indian customer wedge, and a credible follow-on plan. Healthcare-specific pitches should explain how the product navigates Indian payer dynamics and the consumer health competitive landscape.

Caveats. The disruptive-models framing means partner attention competes across thesis areas; ask directly about the firm’s healthcare-specific deployment pace. The firm’s healthcare-specific portfolio is concentrated in CureSkin and a few adjacent consumer health bets; reference calls with health-sector founders are advisable. The check size is moderate; for founders raising larger seeds, India Quotient should be a participant alongside a real lead. For Indian AI-enabled consumer or B2B health-tech founders, India Quotient is a credible early partner with demonstrated category interest; for deep clinical or non-Indian founders, the fit is weaker.